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Abstract: Rare diseases (RD) are characterized by low prevalence and affect not more 
than five individuals per 10,000 in the European population; they are a large and 
heterogeneous group of disorders including more than 7,000 conditions and often involve 
all organs and tissues, with several clinical subtypes within the same disease. Very often 
information concerning either diagnosis and/or prognosis on many RD is insufficient. 
microRNAs are a class of small non-coding RNAs that regulate gene expression at the 
posttranscriptional level by either degrading or blocking translation of messenger RNA 
targets. Recently, microRNA expression patterns of body fluids underscored their potential 
as noninvasive biomarkers for various diseases. The role of microRNAs as potential 
biomarkers has become particularly attractive. The identification of disease-related 
microRNAs is essential for understanding the pathogenesis of diseases at the molecular 
level, and is critical for designing specific molecular tools for diagnosis, treatment and 
prevention. Computational analysis of microRNA-disease associations is an important 
complementary means for prioritizing microRNAs for further experimental examination. In 
this article, we explored the added value of miRs as biomarkers in a selected panel of RD 
hitting different tissues/systems at different life stages, but sharing the need of better 
biomarkers for diagnostic and prognostic purposes. 
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1. Introduction 
According to the Regulation EC n.141/2000, rare diseases (RD) are defined on the basis of low 
prevalence and affect not more than five individuals per 10,000 in the European population [1].  
In the USA the Orphan Drug Act of 1983 defines a RD as “any disease or condition that affects less 
than 200,000 people in the United States”. In Japan, the Japanese Medicines Act of 1993 defines a rare 
disease as a condition affecting no more than 50,000 people in the country.  
They are a large and diverse group of disorders, estimated to include more than 6000 conditions, 
often involving all organs and tissues with several clinical subtypes within the same disease. Several 
groups of RD include congenital malformations, metabolic defects, rare tumors, skin diseases, 
syndromes involving body systems such as the nervous, immune, excretory, reproductive, cutaneous 
ones. About 80% of RD have genetic origins, involving one or several genes or chromosomal 
abnormalities; in many cases the clinical phenotype and prognosis appear to be modulated by yet 
unknown factors, such as different mutations in the same gene(s) or also epigenetic factors. 
The difficulty in obtaining the correct diagnosis is the first dramatic hurdle for rare disease patients. 
It has been estimated that about 30% of RD are still lacking a diagnostic definition; moreover, many 
RD cases get an accurate diagnosis late, even after five years or more from disease recognition. Late 
diagnoses delay specific treatments and might have severe, irreversible, debilitating and life-threatening 
consequences [2]. 
Accurate and timely diagnosis is often of principal importance for prevention and properly targeted 
treatment; where these are unavailable, timely diagnosis is always important for protecting the patients’ 
quality of life. However, due to problems associated with rarity (low number of patients, weak interest 
by research institutions, etc.), information on many RD are insufficient concerning either diagnosis 
and/or prognosis.  
Biomarkers are measurable bio-parameters that can be used to monitor disease progression, 
prognosis and drug response, thus optimizing the choice of appropriate and often personalized 
therapies. Their identification in RD is often impaired by the low number of cases available for each 
disease, making a sound evaluation of sensitivity, specificity, and predictive value difficult. In 
particular, some groups of RD, such as inherited disorders and rare tumors, are insufficiently 
elucidated from the standpoint of pathogenesis and biomarkers.  
Furthermore, it is now well ascertained that RD suffer from the relative lack of information from 
natural history studies of diseases. The specificities of rare diseases―limited number of patients and 
scarcity of relevant knowledge and expertise―can be tackled through a global approach. Very 
recently, an international effort (International Rare Disease Research Consortium, IRDiRC) has been 
formed under the auspices of the US National Institutes of Health (NIH) and the European 
Commission (EC) with the ambitious goal of developing a diagnostic tool for every known rare disease 
by 2020, along with new therapies to treat 200 of them [3]. 
2. microRNA: Function and Role  
microRNAs (miRs) are regulated and transcribed like protein coding genes. Subsequent miR 
biogenesis involves discrete processing and transport steps, whereby the active moiety of 20–22 Int. J. Mol. Sci. 2011, 12 6735 
 
 
nucleotides is excised from a longer RNA precursor that exhibits specific hairpin structure. Finally, 
these 20–22 nucleotides are incorporated into a composite machinery, which promotes partial duplex 
formation between the short RNA and the untranslated regions (UTR) of targeted mRNAs, resulting 
typically in translational silencing in mammals. 
Although the total number of miR remains controversial and their roles are only beginning to be 
defined, miR expression analyses indicate that diverse tumors display miRs expression profiles (for 
mature and/or precursor miRs) significantly different from normal tissue. Furthermore, miRs are 
emerging as highly tissue-specific biomarkers with potential clinical applicability for defining the 
cancer origin of metastases. They have been appreciated in various fundamental biological processes 
such as cell proliferation [4], stem cell division [5] and apoptosis [6]. Recently, it has been revealed that 
altered expression of specific miR genes contributes to the initiation and progression of cancer [7–9]. 
Translational studies suggest that their signature may be useful in categorizing and predicting the 
course of an increasing number of human pathologies.  
3. Diagnostic Utility of miRs and Efficacy as Potential Biomarkers 
Future research targets integrate sets of new biomarkers to be developed with a system biology 
approach and in combination with bioinformatics tools, to devise powerful diagnostic and prognostic 
algorithms. Ideally, biomarkers should be easily accessible such that they can be sampled non-invasively. 
Therefore biomarkers that can be sampled from body fluids, such as serum or urine, are particularly 
desirable. In recent years it has become clear that miRs could represent new effective biomarkers.  
miRs as a diagnostic tool might be used to detect an increased risk of acquiring RD and cancer by 
studying disease associated variations of miR sequences (like miR-146a in thyroid cancer) [10]; to 
diagnose early-stage cancer by determining miR expression profiles in the blood, like miR-141 in 
prostate cancer [11]; to distinguish tumor from normal tissue in fine-biopsy specimens by miR 
expression profiling [7]; and to predict clinical outcome, like in leukemia [12]. Furthermore, human 
genetic variation potentially inﬂuences many medical conditions. Genetic variation can either broadly 
affect miR biogenesis or speciﬁcally hit a miR or its target. The resulting misregulation of miRs and 
their targets is potentially crucial to pathogenesis [13,14]. In genome wide association studies (GWAS), 
copy number variation (CNV) and single nucleotide polymorphisms (SNPs) within the sequences of 
human miRs and their targets have been shown to have impact on various phenotypes including blood 
pressure, drug resistance, mental disorder, gastric mucosal atrophy and Parkinson disease [15]. 
Usefulness of miRs as new effective biomarkers is due to the fact that (i) miRs expression is known 
to be aberrant in cancer; (ii) miRs expression profiles are pathognomonic, or tissue-specific; (iii) over 
expression or lack of expression of specific miRs appear to correlate with clinically aggressive or 
metastatic phenotypes; (iv) miRs are remarkably stable molecules being well preserved in formalin 
fixed, paraffin embedded tissues, fresh snap frozen specimens and body fluids. 
Very few studies have been reported on possible alternative mechanisms underlying specific RDs 
onset and clinical manifestations and progression. This causes the lack of diagnostic/prognostic 
markers that are strongly needed for an adequate follow-up of patients, currently based only on 
classical screenings. Int. J. Mol. Sci. 2011, 12 6736 
 
 
The identification of miRs associated with human diseases is an important goal of biomedical 
research. Recently, a number of computational methods have been developed to predict or prioritize 
diseases-related genes. Most approaches are based on the idea that dysfunctions of functionally related 
genes tend to be associated with phenotypically similar diseases. These genes linked to similar diseases 
usually interact with each other or participate in the common biological modules. Network-based 
approaches have also been employed to predict or prioritize new candidate disease genes based upon 
network linkages with known disease genes. These approaches typically start with constructing a   
gene-gene association network based on one or more types of genomic and proteomic information, and 
then prioritize candidate protein-coding genes based on network proximity to known disease-related 
genes [16]. 
4. microRNA and Rare Diseases  
Even though few studies are available on miRs and their association with RDs, some evidence  
is emerging on their role in controlling pathways involved in RDs onset and/or progression. In   
this paragraph we briefly review the latest findings on selected RDs hitting different tissues/systems at 
different life stages, but sharing the need of better biomarkers for diagnostic and prognostic purposes 
(Table 1). 
Table 1. Rare disease and microRNAs. 
Rare Disease  miR   Note   References 
Duchenne muscular dystrophy 
miR-206, miR-181, miR-1, 
miR-133, miR-29 
Up- and downregulated  [17-25] 
Amyotrophic lateral sclerosis  miR-206  Downregulated  [26] 
Sézary syndrome 
miR-21, miR-214, miR-486, 
miR-18a, miR-342, miR-31, 
let-7, miR-233, miR-199a  
Up- and downregulated  [27–30] 
Rett syndrome 
miR-146a, miR-146b,  
miR-130, miR-122a,  
miR-342, miR-409 
miR-29b, miR-329,  
miR-199b, miR-382, miR-296, 
miR-221, miR-92 
Up- and downregulated   [31] 
Multiple osteochondromas 
miR-21, miR-140, miR-145, 
miR-214, miR-195, miR-451, 
miR-483 
Up- and downregulated  [32] 
Hailey-Hailey disease 
miR-181a, miR-125b, miR-99, 
miR-106a 
Up- and downregulated  [33–39] 
Hepatoblastoma 
miR-214, miR-199a, miR-150, 
miR-125a, miR-148a,  
miR-492 
Up- and downregulated  [40,41] 
Duchenne muscular dystrophy (DMD, OMIM 310200) is a lethal X-linked disorder caused by 
mutations in the dystrophin gene, which encodes a cytoskeletal protein, dystrophin. It has been 
recently demonstrated that the serum levels of muscle-specific miRs (miR-1, miR-133, miR-206) are Int. J. Mol. Sci. 2011, 12 6737 
 
 
released in to the bloodstream of DMD patients [17]; increased level of miRs has also been observed in 
the dystrophin-deficient mouse model, as well as the canine X-linked muscular dystrophy in Japan dog 
model [18]. Recent works have shown that among genes which are important for proper muscle 
development and function, miRs play a crucial role [19–21]. Moreover, altered levels of miRs were found 
in several muscular disorders such as myocardial infarction [22], DMD, and other myopathies [23,24]. 
Yuasa and colleagues [25] showed that miR-206 expression was increased after cardiotoxin-induced 
muscle regeneration and that miR-206 contributes to muscle regeneration. Interestingly, it has been 
showed that the expression levels of miR-206 in DMD patients are not increased [23] or that the 
increase is not as large as in mouse model [24].  
Amyotrophic lateral sclerosis (ALS, OMIM 105400) is a neurodegenerative disease characterized 
by loss of motor neurons, denervation of target muscles, muscle atrophy, and paralysis. Williams and 
colleagues showed that a key regulator of this RD is the miR-206, a skeletal muscle-specific miR that 
is dramatically induced in a mouse model of ALS. Mice that are genetically deficient in miR-206 form 
normal neuromuscular synapses during development, but deficiency of miR-206 in the ALS mouse 
model accelerates disease progression. MiR-206 is required for efficient regeneration of neuromuscular 
synapses after acute nerve injury, which probably accounts for its salutary effects in ALS [26]. 
Sezary syndrome (SS) is a rare and aggressive leukemic variant of cutaneous T-cell lymphoma 
(CTCL) characterized by the presence of neoplastic lymphocytes named Sezary cells, in the skin, 
lymph nodes and peripheral blood [27]. Expression patterns of miRs and their role in the pathogenesis 
of SS have only recently been addressed. Ballabio and colleagues reported that 104 out of 114   
SS-associated miRs were down-regulated and that their expression pattern was consistent with 
previously reported genomic copy number abnormalities Altered level of miR-223 was able to 
discriminate SS samples from healthy controls; down-regulation of intronically encoded miR-342 
plays a role in the pathogenesis of SS by inhibiting apoptosis, and describe a novel mechanism of 
regulation for this miR [28]. Another study conducted on a cohort of 22 SS patients, the expression 
profile of 470 miRs, conducted to the identiﬁcation of 45 miRs differentially expressed between SS 
and controls. Using predictive analysis, a list of 19 miRs, including miR-21, miR-214, miR-486, miR-18a, 
miR-342, miR-31 and let-7 members were also found. Moreover, a signature of 14 miRs including 
again miR-21, potentially able to discriminate patients with unfavorable and favorable outcome, was 
identified [29]. van der Fits and colleagues showed that miR-21 expression is increased in SS cells 
when compared with CD4+ T cells from healthy donors. Silencing of miR-21 in SS cells results in 
increased apoptosis, suggesting a functional role for miR-21 in the leukomogenic process, thus 
representing a putative therapeutic target for the treatment of SS [30].  
Rett syndrome (RTT, Online Mendelian Inheritance in Man Database 312750) is a complex 
neurological disorder that has been associated with mutations in the gene coding for the methyl CpG 
binding protein 2 (Mecp2). This X-linked neurological disorder causes a severe phenotype in one out 
of every 10,000–15,000 live births, making it the second most frequent cause of mental retardation in 
females. Very recently it has been examined the possible effects of miR misregulation caused by 
Mecp2 absence in a mouse model of RTT. Using miR expression microarrays, it was observed that the 
brain of Rett syndrome mice undergoes a disruption of the expression profiles of miRs. Among the 
significantly altered miRs (26%, 65 of 245), overall downregulation of these transcripts was the most 
common feature (71%), while the remaining 30% were upregulated. In particular it was demonstrated Int. J. Mol. Sci. 2011, 12 6738 
 
 
that the most commonly disrupted miRs were miR-146a, miR-146b, miR-130, miR-122a, miR-342 and 
miR-409 (downregulated) and miR-29b, miR329, miR-199b, miR-382, miR-296, miR-221 and   
miR-92 (upregulated) [31]. 
Multiple osteochondromas (MO, OMIM 133700) are characterized by a large spectrum of germline 
mutations scattered along EXT1/EXT2 genes, by the presence of a significant percentage of patients 
without alterations in the EXT genes and a large phenotypic intra- and interfamilial variability. The 
molecular basis of MOs genetic and clinical heterogeneity are currently unknown. This leads to the 
lack of appropriate diagnostic/prognostic markers as well as of therapeutic options for both benign  
and malignant lesions. 45 miRs have been identified as differentially expressed in MO patients, and 
classified them into 4 classes according to their expression compared to articular and/or growth plate 
cartilage. In particular a signature of 8 miRs (namely: miR-21, miR-140, miR-145, miR-214, miR-195, 
miR-199a, miR-451, and miR-483) was able to distinguish healthy growth control from MO patients. 
Compared to microarray data clustering, this finding allows to more accurately identify miRs 
specifically related to pathologic condition of growth plate cartilage. Results indicate that miRs 
differentially expressed may hamper the molecular signaling responsible for normal proliferation and 
differentiation of chondrocytes, thus contributing to pathogenesis and clinical outcome [32]. 
Hailey-Hailey disease (HHD, OMIM 169600) is an autosomal dominant disorder characterized by 
suprabasal cutaneous cell separation leading to the development of erosive and oozing skin lesions. 
While a strong relationship exists between mutations in the gene ATP2C1 and HHD, a poor 
understanding of how these mutations affect manifestations of the disease is available. A specific 
signature discriminating lesion from normal skin was recently found.  The authors found, that   
miR-181a, miR-125b, and miR-99a expression increases in HHD-lesion derived keratinocytes. 
Interestingly, the expression of miR-181a, miR-125b and miR-99a has an anti-proliferative effect in 
several cell types [33–35]. Additionally, miR-106a aberrantly expressed in primary tumors and cancer 
derived cell lines [36] was found to be downregulated in HHD-lesion derived keratinocytes. Collectively, 
these results suggest that a perturbed expression for these miRs in HHD skin lesion may contribute to 
hypo-proliferation of keratinocytes. Computational analysis to identify lesion-specific miRs with the 
most interesting and promising pathogenetic function identified miR-125b as the most significantly 
induced [37,38]. MiR-125b has been found to be also involved in the TNF-alpha pathway and 
deregulated in psoriasis and atopic eczema [39]. 
The Hepatoblastoma (HB, OMIM 114550) is a rare pediatric liver tumor with an incidence in 
Western countries of 1.5 cases per million of individuals younger than 15 years. Despite this, it is the 
most common hepatic malignancy during childhood. Although specific chromosome aberrations have 
not been linked with prognosis or casual factors, genetic disorders have been described in 
chromosomes 1q, 2q, 7q, 8, 17q and 20 as well as activation of Wnt signaling pathway through 
mutations in its central mediator beta-catenin. Whole genome analysis of miRs showed that 4 miRs 
were significantly upregulated in the tumor compared with the nonmalignant tissue (miR-214,   
miR-199a, miR-150, and miR-125a) and one was significantly downregulated (miR-148a). Among 
these, miR-214 has been shown to be deeply involved in controlling the level of PTEN protein, a 
negative regulator of the PI3K signaling whose alteration has been shown to give rise to different 
cancers [40]. Finally, recent work showed a functional relationship between Keratin 19 and miR-492 
that may play an important role in the progression of malignant embryonal liver tumors. The author Int. J. Mol. Sci. 2011, 12 6739 
 
 
stated that co-regulation of miR-492 and keratin 19 expression in HB, occurs predominantly in 
metastatic tumors, providing novel experimental evidence that miR-492 could represent a marker of 
aggressive tumor behavior. MiR-492 and its associated targets might serve as promising biomarker 
candidates in both diagnostic and therapeutic strategies aiming at improving outcome of HB [41]. 
4. Perspectives 
The use of miRs as biomarkers is a promising field. Their basic biology is still being elucidated and 
questions regarding tissue-specific functions and targets, developmental time of expression, regulation 
and evolutionary role are being explored. With their key roles in gene expression regulation, 
particularly during cell differentiation and tissue genesis, miRs are probably critical in cancer initiation 
and progression, but more research studies are needed to explore their impact as clinical biomarkers 
for cancer and disease diagnosis, prognosis and prediction of therapeutic response. Outputs of this new 
field will be the identification of molecular markers to detect potential therapeutic targets, new 
biomarkers which could improve diagnosis and management, optimize patients’ follow-up and, in turn, 
improve their quality of life. The development of minimally invasive tests for the detection and 
monitoring of RD can reduce their worldwide health burden. Although conventional strategies for 
blood-based biomarker discovery (e.g., using proteomic technologies) have shown promise, the 
development of clinically validated cancer detection markers remains an unmet challenge for many 
common human cancers. It is strongly believed that studies on the biological basis of the above 
mentioned pathologies will improve their understanding and support the development of perspective 
therapies. The identification of others disease-related miRs is extremely important for understanding 
the pathogenesis of diseases at the molecular level and is critical for designing specific molecular tools 
for diagnosis, treatment and prevention. 
5. Conclusions 
More than 1500 transcribed miRs have been identified in the human genome since their discovery. 
miR analysis is a promising tool for identifying new biomarkers, as well as for predicting response to 
cancer and rare diseases therapy. Recently, several reports suggest that cell-free circulating miRs are 
detectable in serum/plasma and the levels of tumor-derived miRs are altered in patients with tongue 
cancer, lung cancer, prostate cancer, ovarian cancer, and colorectal cancer (reviewed in this issue). 
These findings suggest that blood-based miRs could emerge as revolutionary sources of biomarker for 
diagnosis. Further understanding of their functional roles will open up new opportunities in developing 
revolutionary therapeutic strategies. Although we are just beginning to understand the specific 
contribution of miRs in RD, a larger sample sets including long-term clinical data are urgently required 
for future studies. Finally, major efforts need to be applied on standardization of isolation, 
quantification and normalization strategies before any of the novel miR biomarkers is applicable for 
clinical practice. Int. J. Mol. Sci. 2011, 12 6740 
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